Labiotech.eu

Interview 14 Nov 2022

MaaT Pharma: leading the charge in microbiome therapeutics

The first generation of microbiome therapeutics is hitting its first approvals. Savita Bernal, chief business officer at the French biotech MaaT Pharma outlines the firm’s efforts to blaze a trail in clinical testing and manufacturing in the new field. The microbiome world recently made a regulatory step forward as Australia greenlit a stool transplant developed […]

November 14, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 14 Nov 2022

Eden Bio raises £1m to boost AI protein yields

Eden Bio, a U.K.-based biotech using machine learning to increase protein yield, has raised £1 million ($1.17 million) from a seed investment round. The company said this strengthens its R&D capacity and ability to expand the underlying machine-learning platform over the coming years. By using artificial intelligence to genetically optimize microorganism strains, the company improves […]

November 14, 2022 - 2 minutesmins - By Jim Cornall

More News! 14 Nov 2022

33 Californie launches new fund for healthcare startups

33 Californie, an investment fund specialized in the healthcare sector, has opened subscriptions for CaLySeed, its second investment fund, providing financial and strategic support to start-ups. The aim of the new initiative is to finance innovations in human health, including therapeutics, medical devices, in vitro diagnostics, e-health, technology platforms and nutraceuticals. CaLySeed will invest in […]

November 14, 2022 - 3 minutesmins - By Jim Cornall

More News! 14 Nov 2022

ChromaTwist lands second round of funding for fluorescent dyes for flow cytometry market

ChromaTwist Ltd, a University of Birmingham spinout, has secured £487,000 ($573,000) of equity investment to develop its new class of fluorescent dyes for the flow cytometry reagent market. Existing investors, Angel from angelgroups and the University of Birmingham brought in funds which will allow ChromaTwist to continue product development with industry partners and enable rapid […]

November 14, 2022 - 4 minutesmins - By Liza Laws

News and Trends 14 Nov 2022

A new treatment for tackling epidermolysis bullosa

By Jordi Casals, president, EMEA, Amryt Pharma Epidermolysis bullosa (EB), sometimes described as “the worst disease you’ve never heard of,” is a group of rare and distressing inherited skin disorders primarily diagnosed in young children. The genetic mutations that cause EB can result in the skin being extremely fragile. Any physical contact with the skin […]

November 14, 2022 - 3 minutesmins - By External Contributor

News and Trends 14 Nov 2022

Altered cell behavior reason for neuroblastoma resistance

Researchers at Lund University in Sweden have identified one of the reasons why the childhood cancer neuroblastoma becomes resistant to chemotherapy. The scientists hope the findings are significant for how future treatments should be designed. The results have been published in the journal Science Advances. Neuroblastoma is an aggressive cancer of the sympathetic nervous system, […]

November 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

New therapy transitions toxic immune cells from harmful to healing to fight effects of hyperinflammation in children

When we think about acute kidney injury (AKI) and multi-organ failure, we don’t often think about children. But approximately 4,000 pediatric patients in the U.S. each year have AKI requiring continual kidney replacement therapy (CKRT). These patient profiles are associated with long hospital stays, high morbidity and mortality (50%), and children who survive an AKI […]

November 14, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

InfanDx tackles early detection of hypoxic ischemic encephalopathy

InfanDx AG, a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, has completed the validation of metabolic biomarker panels for the early detection of hypoxic ischemic encephalopathy (HIE) in newborns. The validated biomarkers of such panels will be the target of the company’s HypoxE blood test for […]

November 14, 2022 - 8 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

RSV cases are rising fast in children. Early detection can help.

By Shawn Gaskell, MilliporeSigma RSV-related hospitalizations for 2022 have already surged to unusually high numbers, surpassing cumulative cases typically reported in late December each year, and we’re not even one month into the season. While no age group is immune to RSV— respiratory syncytial virus— and the trouble it can cause, young children are being […]

November 14, 2022 - 5 minutesmins - By External Contributor

Interview 14 Nov 2022

In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus

AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the European Union (EU) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. Beyfortus is the first and only single-dose RSV passive immunization for the broad infant population, including those born healthy, at term […]

November 14, 2022 - 9 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

Early diagnosis tool for childhood kidney disease

Early diagnosis of chronic kidney disease (CKD) is key to managing progression of the disease. A new technique analyzing urine extracellular vesicles (uEVs) — cell-derived nanoscale spherical structures involved in multiple biological functions — in urine samples, identifies changes in the kidneys earlier than conventional methods and can also predict renal function decline. A team […]

November 14, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

A biotech boom manifesting real results in rare pediatric diseases

By Bob Coughlin, managing director, life sciences, JLL For the last two years, the pandemic has resulted in the explosive growth in life sciences. The world watched in awe and anticipation as biotech successfully raced to develop vaccines, therapeutics and diagnostics for Covid-19. It has been a good moment for an industry that deserves such […]

November 14, 2022 - 5 minutesmins - By External Contributor

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

MaaT Pharma: leading the charge in microbiome therapeutics

Eden Bio raises £1m to boost AI protein yields

33 Californie launches new fund for healthcare startups

ChromaTwist lands second round of funding for fluorescent dyes for flow cytometry market

A new treatment for tackling epidermolysis bullosa

Altered cell behavior reason for neuroblastoma resistance

New therapy transitions toxic immune cells from harmful to healing to fight effects of hyperinflammation in children

InfanDx tackles early detection of hypoxic ischemic encephalopathy

RSV cases are rising fast in children. Early detection can help.

In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus

Early diagnosis tool for childhood kidney disease

A biotech boom manifesting real results in rare pediatric diseases

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!